Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Consolidated Net Income: 2012-2025

Historic Consolidated Net Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Consolidated Net Income rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
  • Enanta Pharmaceuticals' Consolidated Net Income amounted to -$18.6 million in Q3 2025, which was down 1.82% from -$18.3 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Consolidated Net Income peaked at -$18.3 million during Q2 2025, and registered a low of -$39.1 million during Q2 2023.
  • Its 3-year average for Consolidated Net Income is -$27.5 million, with a median of -$28.1 million in 2023.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Consolidated Net Income tumbled by 503.91% in 2021, and later soared by 42.00% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Consolidated Net Income (Quarterly) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then declined by 15.25% to -$33.4 million in 2023, then soared by 33.28% to -$22.3 million in 2024, then spiked by 35.08% to -$18.6 million in 2025.
  • Its Consolidated Net Income was -$18.6 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.